Harmony Biosciences Holdings HRMY 深 滬
已收盤 10-24 16:00:00 美东时间
30.25
+0.650
+2.20%
華盛通- 最 高30.3781
- 今 開29.73
- 成交量 93.35万股
- 最 低 29.57
- 昨 收 29.60
- 總市值 17.40亿
- 52周最高 40.93
- 市盈率 靜 12.03
- 換手率 1.62%
- 52周最低 25.52
- 委 比 -92.01%
- 總股本 5753.26万
- 歷史最高 62.085
- 量 比 1.05
- 振 幅 2.73%
- 歷史最低 18.6112
- 每 手 1
- 風險率 3.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harmony Biosciences Reports Record Q3 2025 WAKIX Revenue Of $239M, Raises Full-Year Guidance From $820M-$860M To $845M-$865M
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary results for Q3 2025, highlighted by the following:WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025,
10-23 20:17
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
UBS Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $43
UBS analyst Ashwani Verma maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $50 to $43.
10-15 23:28
Top 3 Health Care Stocks That Are Preparing To Pump In Q4
The most oversold stocks in the health care sector presents an opportunity to b...
10-06 18:23
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points o...
09-25 02:18
Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $41
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $48 to $41.
09-24 22:29
Harmony Biosciences Stock (HRMY) Sinks on Failed Phase 3 Study
Harmony Biosciences stock fell hard on Wednesday after the company posted poor ...
09-24 20:27
Harmony Biosciences shares are trading lower. Needham lowered its price target on the stock from $49 to $48.
Harmony Biosciences shares are trading lower. Needham lowered its price target ...
09-10 01:32
